Clinical Trial Search

Primary: Efficacy Endpoints for Part 1 of the Study is Progression-free Survival at 6 Months (PFS6) — 0; 0; 0; 9 Participants

Primary: Overall Response Rate — 1; 20; 10; 4 Participants

Primary: Number of Participants With Dose-limiting Toxicity (DLT): Phase I Only — 10.0; 0; 0; 4.3 Percentage of participants

Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005

Primary: Time to Progression — 7.7 Months

Primary: Dose Limiting Toxicity — 0; 0; 0 Participants

Primary: Progression-free Survival (PFS) — 23.1 percentage of participants

Primary: Substudy 1: Objective Response Rate (ORR) — 22.3 Percentage of participants

Primary: Phase Ib: Patients With Event(s) of Dose-limiting Toxicity — 0; 0 Participants

Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months

Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg

Primary: Time to Disease Progression — 8 months

Primary: Number of Subjects With Overall Survival — 16; 4; 34; 24 Participants — p=0.536

Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM

Primary: Clinical Benefit Rate (Percentage), Which Includes Confirmed Tumor Response (Complete Response [CR] or Partial Response [PR]) or Stable Disease (SD) — 45.5 percentage of…

Primary: Calculation of M Scores and HCC Probability Scores — 1.113; 1.159; 1.797; 1.707 units on a scale

Primary: Overall Response Rate (ORR) — 13.3 percentage of participants

Primary: Overall Survival — 333; 290 days — p=0.4593

Primary: Treatment Response — 16; 14; 4 Participants

Primary: Number of Patients With Drug-related Treatment-emergent Adverse Events (TEAEs) — 3; 1; 1; 11 Participants

Primary: Patient Survival — 5; 6; 4; 10 participants — p=0.4340

Primary: Disease Control Rate (DCR) at 16 Weeks for Patients Treated With Guadecitabine After Failure of Sorafenib — 25.0; 24.4 percentage of patients

Primary: Time to Progression (TTP) — 164; 112 days

Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa

Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001

Primary: Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD) — NA; 20 Milligrams

Primary: Phase 1b: Number of Participants Experiencing Dose Limiting Toxicity (DLT) According to National Cancer Institute Common Toxicity Criteria (NCI-CTCAE) for Adverse Events…

Primary: Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET — 0 Participants

Primary: Time to Tumor Progression (TTP) for TRC105 in Hepatocellular Carcinoma (HCC). — 12 Weeks

Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…